Related by context. All words. (Click for frequent words.) 70 estrogen receptor negative 69 HNSCC 68 ADPKD 68 estrogen receptor ER 68 tumor histology 67 lymph node metastasis 67 gastric carcinoma 67 hormone receptor negative 66 node metastases 66 pancreatic adenocarcinoma 66 atypical hyperplasia 66 Leydig cell 66 TT genotype 66 advanced adenomas 66 MYCN amplification 66 CIN3 66 mucinous 65 prostate cancer CaP 65 HER2 expression 65 anaplastic 65 KRAS mutations 65 lymph node involvement 65 nodal metastasis 65 microbleeds 65 B7 H3 65 prognostic indicator 64 endometrial cancers 64 invasive carcinoma 64 GISTs 64 neurofibromas 64 benign moles 64 operable breast cancer 64 CC genotype 64 androgen deficiency 64 lymphovascular invasion 64 BRCA1 mutation carriers 64 androgen deprivation 64 colorectal carcinoma 64 estrogen receptor positive 64 Hashimoto thyroiditis 64 carotid stenosis 64 progesterone receptor negative 64 malignant prostate 63 nonmelanoma skin cancers 63 thyroid carcinoma 63 penetrance 63 basal cell nevus syndrome 63 osteopenic 63 contralateral breast 63 liver metastasis 63 BRCA1 mutations 63 nonischemic cardiomyopathy 63 infarcts 63 nodal metastases 63 prostate carcinoma 63 subclinical hyperthyroidism 63 pCR 63 BRAF mutation 63 histologic subtype 63 urothelial carcinoma 63 BRAF V#E mutation 63 G allele 63 colorectal neoplasms 63 EGFR mutation 63 lobular carcinoma 63 grade gliomas 63 GSTT1 63 metastatic gastric 63 PSADT 63 PCNSL 63 pheochromocytomas 63 shorter telomeres 63 K ras mutations 63 gastric cardia 63 mammary cancers 63 malignant neoplasm 63 ductal breast cancer 62 squamous cell carcinoma SCC 62 subclinical hypothyroidism 62 microsatellite instability 62 invasive ductal 62 hyperplastic 62 gastric adenocarcinoma 62 MGUS 62 PTPN# 62 rs# [002] 62 adenoma 62 PCa 62 LV dysfunction 62 unresectable tumors 62 premalignant 62 APOE ε4 62 VEGF expression 62 cervical lesions 62 nonalcoholic steatohepatitis NASH 62 extracapsular extension 62 estrogen receptor progesterone receptor 62 Basal cell 62 histological subtype 62 premalignant lesions 62 cervical lymph nodes 62 biochemical recurrence 62 carotid plaques 62 transferrin saturation 62 brain lesions 62 neoplastic lesions 62 mammary tumors 62 endometrial thickness 62 ovarian carcinoma 62 leiomyomas 62 antiphospholipid antibodies 62 TNF blocker therapy 62 epithelial tumors 62 Sjögren syndrome 62 p# mutations 62 nonmetastatic 62 arterial thickening 62 HER2 receptor 62 colorectal adenoma 62 thyroid nodules 62 BRCA mutation 62 HER2 positive tumors 62 prostate pancreatic 62 castration resistant 62 EGFR mutations 62 papillary 62 neoplasia 62 HER2 amplification 62 supratentorial 62 EGFR mutation positive 62 neurofibroma 62 genital tract infections 62 chronic periodontitis 62 HER2 positive cancers 62 #.#ng/ml 62 situ LCIS 62 carotid IMT 62 elevated CRP 62 neoplasias 61 obstructive coronary artery 61 gastric atrophy 61 IDH mutations 61 white matter hyperintensities 61 malignant lymphoma 61 lung metastasis 61 TGFBR1 * 6A 61 RET PTC rearrangements 61 p# mutation 61 hyperplastic polyps 61 basal cell carcinoma BCC 61 GBA mutations 61 esophageal squamous cell carcinoma 61 paragangliomas 61 SLNB 61 Papillary 61 axillary lymph nodes 61 preoperative chemotherapy 61 hamartomas 61 precancerous condition 61 subcortical 61 colonic polyps 61 chlamydial infection 61 colorectal tumors 61 atherosclerotic lesions 61 normal karyotype 61 sarcomatoid 61 hormone deprivation 61 elevated triglyceride levels 61 malignant transformation 61 polypoid lesions 61 coinfection 61 Prostatitis 61 breast carcinoma 61 lymph node metastases 61 TOP2A 61 taxane therapy 61 advanced adenoma 61 invasive lobular carcinoma 61 endometrial carcinoma 61 troponin T 61 ASCUS 61 platelet reactivity 61 adenocarcinomas 61 hypermethylated 61 invasive lobular 61 neoplastic 61 hepatocellular 61 thyroid hormone levels 61 APOE e4 61 EBV infection 61 proliferative diabetic retinopathy 61 hypercoagulable 61 nodular melanoma 61 prognostic factor 61 adenomatous polyps 61 HbF 61 noncalcified 61 metastatic bladder 61 gene polymorphism 61 aminotransferase levels 61 solar keratosis 61 pAkt 61 breast endometrial 61 Adjuvant chemotherapy 61 dysplastic nevi 61 metabolic abnormalities 61 preoperative PSA 61 narcolepsy cataplexy 61 grade cervical intraepithelial 61 metastatic lesions 61 neurocognitive deficits 61 squamous cell cancers 61 colorectal neoplasia 61 renal cell carcinomas 61 precancerous cervical 61 immunoreactivity 61 NP CRNs 61 arterial calcification 61 thyrotoxicosis 61 thyroglobulin 61 prognostic marker 61 telomere lengths 60 obstructive CAD 60 CP CPPS 60 differentiated thyroid 60 MMSE scores 60 ERBB2 60 distant metastases 60 lymphocytic 60 orchitis 60 nonseminoma 60 ABCB1 60 microvascular disease 60 hypogonadotropic hypogonadism 60 HER2 overexpression 60 progesterone receptor PR 60 lobular 60 histopathologic examination 60 Multivariate analyzes 60 extracranial 60 minimally symptomatic 60 anterior temporal 60 heterotaxy 60 2D 4D ratio 60 lymphomas leukemias 60 Cholangiocarcinoma 60 chemoresistant 60 proximal colon 60 Genetic variants 60 metachronous 60 cervical carcinoma 60 Barrett mucosa 60 serum estradiol 60 seminal vesicle invasion 60 BRCA2 mutation 60 HGPIN 60 squamous cell lung cancer 60 circulating EPCs 60 chromosomal rearrangement 60 HER2 positive breast 60 CIN2 + 60 BRCA mutations 60 mutated K ras 60 PCA3 scores 60 oral squamous cell 60 metaplasia 60 Hurthle cell 60 KRAS oncogene 60 hepatocellular carcinomas 60 periventricular 60 mutated KRAS 60 intima media thickness 60 untreated celiac disease 60 recurrent ovarian 60 SOD2 gene 60 prognostic significance 60 homozygotes 60 shorter telomere length 60 clinically detectable 60 renal dysfunction 60 EpCAM expression 60 familial adenomatous polyposis 60 heterozygous 60 hypertrophic scars 60 hematopoietic cancers 60 renal tumors 60 precursor lesions 60 cardiac dysfunction 60 familial ALS 60 oropharyngeal cancer 60 postoperative mortality 60 cutaneous melanoma 60 SHBG levels 60 pituitary adenomas 60 hereditary predisposition 60 axillary nodes 60 APOE4 60 perimenopausal women 60 morphologic 60 de novo mutations 60 meningiomas 60 neurocognitive impairment 60 intact parathyroid hormone 60 familial pancreatic cancer 60 MetS 60 NAFLD 60 HER2 negative 60 fractional anisotropy 60 HGPS 60 serum creatinine levels 60 atypical ductal hyperplasia 60 subclinical atherosclerosis 60 CD#c 60 prostate abnormalities 60 prostate adenocarcinoma 60 lactate dehydrogenase 60 inherited predisposition 60 artery stenosis 60 MTHFR 60 germline mutations 60 BRCA2 mutations 60 GSTP1 60 Squamous 60 tumoral 60 familial clustering 60 stratifying patients 60 diabetes mellitus DM 60 SUVmax 60 leucopenia 60 prognostic factors 60 Peutz Jeghers syndrome 60 BRCA mutation carriers 60 beta blocker therapy 60 adrenocortical 60 underlying pathophysiology 60 scintigraphic 60 ERCC1 60 colonic mucosa 60 benign prostate 60 AAT deficiency 60 cTnT 60 malignant lesions 60 metastatic prostate 60 lichen planus 60 lung carcinomas 60 neoplasm 60 Carcinoid tumors 60 epithelial ovarian 60 immunocompetent 60 atherosclerotic lesion 60 MLH1 60 intestinal metaplasia 60 BRCA gene mutation 59 urinary tract symptoms LUTS 59 neurological abnormalities 59 chemosensitivity 59 euthymic patients 59 cytogenetic abnormalities 59 ApoE4 59 testicular germ cell 59 parkinsonism 59 seminomas 59 pT3 59 calcified plaques 59 intraventricular hemorrhage 59 thyrotropin levels 59 severe periodontitis 59 prognostic indicators 59 choroidal neovascularization 59 carcinoid tumor 59 epithelial ovarian cancer 59 multivariate adjustment 59 sentinel lymph node biopsy 59 rs# [001] 59 BRCA2 gene mutation 59 serous ovarian cancer 59 osteosarcomas 59 inherited mutations 59 abnormal glucose tolerance 59 neuroblastomas 59 adjuvant radiotherapy 59 distal colon 59 adenomatous 59 de novo AML 59 atypia 59 basal cell cancers 59 adnexal mass 59 xenograft tumors 59 rs# [004] 59 carbohydrate intolerance 59 Colon polyps 59 neurocognitive function 59 hyperinsulinemia 59 noncarriers 59 hydroxyvitamin D levels 59 T2DM 59 BMPR2 59 hormone receptor positive 59 BRAF mutations 59 comorbid disorders 59 Circulating tumor cells 59 polyp recurrence 59 MnSOD 59 pituitary adenoma 59 motor neuron degeneration 59 breast carcinomas 59 axillary node 59 LV hypertrophy 59 Endometrial cancer 59 oligodendroglioma 59 p# activation 59 osteoblastic 59 carcinoids 59 colorectal liver metastases 59 epididymal 59 dopamine receptor gene 59 pancreatic prostate 59 IL#B 59 WT1 59 abnormal glucose metabolism 59 RASSF1A 59 aminotransferases 59 postnatally 59 intestinal polyps 59 pg ml 59 nonischemic 59 MC1R 59 chloride secretion 59 endometrial hyperplasia 59 hormone receptor status 59 MALT lymphoma 59 cell carcinomas 59 graft dysfunction 59 nonalcoholic steatohepatitis 59 breast cancer subtypes 59 chromosomal instability 59 lobular cancer 59 adverse cytogenetics 59 cerebral infarction 59 multivessel disease 59 clinically insignificant 59 skeletal metastases 59 Endothelial dysfunction 59 hypervascular 59 thyrotropin 59 hsCRP levels 59 gene polymorphisms 59 hyperintensities 59 benign breast 59 familial hypercholesterolemia 59 SNP rs# [002] 59 radiosensitive 59 bladder carcinoma 59 extrapyramidal symptoms 59 MYH9 gene 59 nonmalignant 59 elevated cortisol 59 histologic 59 FGFR2 gene 59 pulmonary metastases 59 mRNA expression 59 gallstone disease 59 GIST tumors 59 carotid plaque 59 RIP1 59 PTEN mutations 59 BRCA2 carriers 59 serum urate levels 59 hematologic toxicity 59 medial temporal 59 Ki# 59 nonfasting triglyceride levels 59 epithelia 59 SLC#A# [002] 59 mesotheliomas 59 primary aldosteronism 59 serum PTH 59 pancreatic endocrine 59 uveal melanoma 59 polypoid 59 BRCA1 mutation 59 fibroids endometriosis 59 gadolinium enhanced 59 adenocarcinoma 59 tertile 59 cranial irradiation 59 deletion 5q 59 coronary calcification 58 epithelioid 58 folate deficiency 58 chorioamnionitis 58 heterozygotes 58 leukocytosis 58 cardiac fibrosis 58 micrometastases 58 purpura 58 glial tumors 58 Chronic pancreatitis 58 comorbid anxiety 58 AGTR1 58 gastric cancers 58 TOP2A gene 58 diffuse gastric 58 Squamous cell 58 BRAF V#E 58 APOE gene 58 infantile hemangiomas 58 NNRTI resistance 58 perineural invasion 58 rCBF 58 cellularity 58 LRP5 58 medically inoperable 58 oligodendrogliomas 58 EGFR protein 58 DQB1 * 58 bullous 58 carcinoid tumors 58 secondary hyperparathyroidism 58 mosaicism 58 hypercalcemia 58 estrogen receptors 58 airflow obstruction 58 varices 58 PAOD 58 fibrous dysplasia 58 CYP#B# 58 nonhereditary 58 urate levels 58 nonmelanoma 58 bullous pemphigoid 58 tumors 58 activated lymphocytes 58 hamartoma 58 unfavorable cytogenetics 58 ductal cancer 58 denser breasts 58 hyperalgesia 58 sporadic ALS 58 elevated serum creatinine 58 endocrine tumors 58 serum markers 58 onset diabetes mellitus 58 BRCA1 BRCA2 58 pheochromocytoma 58 adrenocortical cancer 58 impair fertility 58 transgene expression 58 castrate resistant 58 ependymoma 58 colorectal adenomas 58 postoperative pulmonary 58 subclinical disease 58 prolonged QT interval 58 malignant ovarian 58 P = .# 58 S#A# [002] 58 hyperintensity 58 Kaposi sarcoma 58 locoregional recurrence 58 radical prostatectomy RP 58 prostate cancer PCa 58 colorectal polyp 58 recurrent glioblastoma multiforme 58 lymphadenopathy 58 chronic hepatitis cirrhosis 58 hepatic lipase 58 hippocampal atrophy 58 bilateral oophorectomy 58 malignant pleural mesothelioma 58 Raf MEK ERK 58 underactive thyroid gland 58 autonomic dysfunction 58 autoregulation 58 small lymphocytic lymphoma 58 bladder cancers 58 angiographically 58 #q# deletion 58 androgen dependent 58 Cowden syndrome 58 squamous cell 58 estrogen deficiency 58 clinicopathological 58 isoenzyme 58 FDG uptake 58 elevated IOP 58 TCF#L# 58 lobular breast cancer 58 neovascular 58 MSMB 58 prostate carcinogenesis 58 hormone refractory 58 Asymptomatic 58 adjuvant radiation 58 juvenile idiopathic arthritis 58 BRCA deficient 58 PlGF 58 vascular dysfunction 58 testicular tumors 58 CYP#D# genotype 58 fusiform 58 ovarian hormones 58 sCJD 58 SSc 58 neuroblastoma tumors 58 POAG 58 esophagogastric junction 58 intracranial stenosis 58 HBeAg negative 58 haematopoietic 58 elevated LDH 58 de ath 58 Rectal cancer 58 pulmonary infiltrates 58 DNA methylation patterns 58 Squamous cell carcinomas 58 malignant nodules 58 macroalbuminuria 58 microvessel density 58 pre malignant lesions 58 neurologic complications 58 leptin deficiency 58 grade squamous intraepithelial 58 peritoneal carcinomatosis 58 ε4 58 plasma folate 58 atypical moles 58 papillary thyroid carcinoma 58 distal colon cancer 58 serum calcium levels 58 recurrent VTE 58 metastatic lymph nodes 58 juvenile idiopathic arthritis JIA 58 axillary lymph node 58 urine cytology 58 Inhibin B 58 contralateral breast cancer 58 PTHrP 58 completely resected 58 psychiatric comorbidity 58 leukopenia 58 systemic amyloidosis 58 Squamous cell cancer 58 recurrent UTI 58 PDE7B 58 hyperparathyroidism 58 TIMP 1 58 Vitamin B# deficiency 58 LVNC 58 syngeneic 58 cytoreductive surgery 58 lumbar disk herniation 58 Osteopenia 58 predisposing factor 58 etiologic 58 parous women 58 cisplatin resistant 58 atypical lobular hyperplasia 58 intravenous bisphosphonates 58 detecting precancerous 58 recurrent ovarian cancer 58 IPAH 58 PSA nadir 58 HIV HCV coinfected 58 TP# mutations 58 CagA 58 GBM tumors 58 locoregional 58 precancerous tumors 58 adenomyosis 58 NKG2D 58 Thal Dex 58 histologic subtypes 58 left ventricular hypertrophy 58 LHRH receptor positive 58 hepatic fibrosis 58 tibolone 58 C. pneumoniae 58 multivariable analysis 58 pulmonary dysfunction 58 impaired endothelial 58 myeloperoxidase 58 paraganglioma 58 T2 lesions 58 Testosterone deficiency 58 epididymitis 58 autoimmune thyroid 58 vulvar intraepithelial neoplasia 58 CAG repeats 58 noncardiac 58 lactate dehydrogenase LDH 58 micrometastasis 58 EBRT 58 lymphopenia 58 hypogonadal 58 hormone therapy estrogen 58 thromboembolic complications 58 imatinib therapy 58 BRCA2 gene 58 perioperative complications 58 osteochondroma 58 curable cancers 58 Uterine fibroids 58 histologically 58 PR interval prolongation 58 subtrochanteric 58 Telomere length 58 chemopreventive agent 58 Diabetic nephropathy 58 autoantibodies 58 squamous cells 58 nonmelanoma skin cancer 58 genetic polymorphisms 58 bronchopulmonary dysplasia 58 Metastatic prostate cancer 58 E selectin 58 primary ovarian insufficiency 58 cortical thinning 57 mesenteric 57 mutated BRAF gene 57 prostate cancers 57 resectable 57 atypical nevi 57 choroidal 57 adenomas 57 regulated kinase ERK 57 meningeal 57 ErbB2 57 dyskeratosis congenita 57 dysplastic 57 fibrocytes 57 papillary carcinoma 57 transitional cell carcinoma 57 catheter angiography 57 lobular involution 57 severe neutropenia 57 cirrhotic liver 57 perioperative morbidity 57 PTEN gene 57 APOE allele 57 microRNA expression 57 microvessels 57 allogeneic HSCT 57 creatinine levels 57 DRB1 * 57 endothelial dysfunction 57 hydrops 57 TMEM#B 57 CD# expression [002] 57 airway hyperresponsiveness 57 leukaemias 57 overt hypothyroidism 57 potentially modifiable 57 fibrosis progression 57 glomerular 57 transfusion syndrome 57 KRAS mutation 57 ductal 57 varicocele 57 prefrontal regions 57 prothrombotic 57 obstructive coronary 57 Gorlin syndrome 57 coronary artery calcification 57 chromosomal aberrations 57 localized renal 57 VCAM 1 57 atherosclerotic disease 57 colorectal adenocarcinoma 57 T1DM 57 atrophic 57 posterior fossa 57 neurodevelopmental outcomes 57 relapsed ovarian cancer 57 serum selenium 57 adiponectin concentrations 57 benign lesions 57 serum phosphate 57 renal fibrosis 57 geographic atrophy 57 chromosomal alterations 57 mutated BRCA1 57 LQTS 57 tumor subtype 57 haematologic 57 HER2 neu 57 neuronal dysfunction 57 EoE 57 CYP#D# gene 57 phthalate syndrome 57 lipid abnormalities 57 nasopharyngeal carcinoma 57 tumor recurrence 57 T1a 57 breast cancer metastasis 57 androgen excess 57 squamous cell cancer 57 metastatic neuroendocrine tumors 57 echogenicity 57 subependymal giant cell 57 serum albumin 57 androgen independent 57 EGFR expression 57 lobular carcinomas 57 metastatic malignant 57 ischemic lesions 57 Prognostic factors 57 TCF#L# gene 57 prognostic variables 57 prefrontal cortical 57 intravesical therapy 57 subclinical 57 aplasia 57 non mutated KRAS 57 clinically localized prostate 57 parathyroid carcinoma 57 CMV infections 57 activating mutations 57 pituitary tumors 57 hemorrhagic complications 57 Doppler sonography 57 cardioembolic stroke 57 polycystic ovary syndrome PCOS 57 advanced neoplasia 57 postoperative delirium 57 PARP inhibition 57 persistent pulmonary hypertension 57 cell adhesion molecule 57 Primary IGFD 57 PKC beta 57 CVD mortality 57 non squamous histology 57 polycystic ovarian syndrome PCOS 57 mtDNA mutations 57 NKX2 57 laterality 57 GRK5 57 sonographic appearance 57 hepatocellular carcinoma HCC 57 oophorectomy 57 systolic dysfunction 57 mitochondrial metabolism 57 postoperative morbidity 57 moderate renal impairment 57 neoplasms 57 cholangiocarcinoma 57 hypovitaminosis D 57 gliomas 57 Angiotensin converting enzyme 57 metastatic malignant melanoma 57 GG genotype 57 Treg cell 57 pre cancerous 57 metastatic lesion 57 thromboembolic events 57 corticosterone levels 57 premenopausal breast cancer 57 susceptibility gene 57 undergoing radical prostatectomy 57 TP# mutation 57 malignant pancreatic 57 NMIBC 57 thyroid nodule 57 Barrett esophagus BE 57 endometrial cells 57 carotid atherosclerosis 57 #q#.# deletion syndrome 57 symptomatic carotid stenosis 57 mammographic density 57 Prostate specific antigen 57 colorectum 57 nondepressed 57 primitive neuroectodermal tumors 57 Heavy menstrual bleeding 57 postoperative chemotherapy 57 parathyroid 57 Ovarian cysts 57 lung adenocarcinoma 57 chromosomal abnormalities 57 distant metastasis 57 anterior uveitis 57 cyclin E 57 tunica vaginalis 57 ventricular tachyarrhythmia 57 autoimmune thyroiditis 57 biochemical relapse 57 molecular subtypes 57 ventricular dysfunction 57 situ CIS 57 MC1R gene 57 colorectal carcinomas 57 bladder tumors 57 choroidal neovascularization CNV 57 Clusterin 57 hyperintense lesions 57 KRAS status 57 malignant brain 57 SRBD 57 dopaminergic therapy 57 nephrotoxicity 57 CDKN2A 57 IV bisphosphonates 57 Ovary removal 57 hypoperfusion 57 metastatic melanomas 57 overexpress HER2 57 homozygosity 57 hepatic metastases 57 radiochemotherapy 57 ADAM# 57 serum prostate 57 albumin excretion rate 57 intensive statin therapy 57 varicoceles 57 ipsilateral 57 lymphocytosis 57 aortic regurgitation 57 breast tumors 57 vestibular schwannomas 57 carcinoembryonic antigen 57 carcinomas 57 pro angiogenic 57 colorectal gastric 57 papillary renal cell carcinoma 57 Pulmonary hypertension 57 PON1 57 oncologic outcomes 57 EGFR mutant 57 phenotype 57 extranodal 57 BRCA2 mutation carriers 57 melanoma lesions 57 metabolic abnormality 57 axillary dissection 57 circulating estrogens 57 albumin excretion 57 PNH patients 57 hypointense 57 GSTM1 57 Neurofibromatosis type 57 coinfected 57 metabolic disturbances 57 adrenal cortex 57 HER2 positivity 57 urothelial bladder cancer 57 echocardiographic parameters 57 preserved ejection fraction 57 CCR5 delta# 57 liver scarring 57 ApoE4 allele 57 UGT#A# * 57 paricalcitol 57 N telopeptide 57 cagA 57 ductal lobular 57 steatohepatitis 57 Her2 positive 57 serum folate concentrations 57 overactivity 57 paraneoplastic 57 airway hyper responsiveness 57 lymphoproliferative disorders 57 underactive thyroids 57 Sezary syndrome 57 SGPT 57 basal cell carcinomas 57 loop diuretics 57 Uveal melanoma 57 carotid artery blockage 57 C#Y 57 NADPH oxidase 57 Akt activation 57 ERalpha 57 cardiovascular disease hypertension 57 pancreatic carcinoma 57 affective psychosis 57 irregular menstrual cycles 57 Radical prostatectomy 57 thymoma 57 methotrexate therapy 57 microangiopathy 57 estrogen receptor 57 eosinophil count 57 pT2 57 BRCA carriers 57 abdominal adiposity 57 SPINK1 57 urothelial cancer 57 seminoma 57 amenorrhoea 57 abnormal clotting 57 non squamous NSCLC 57 cystectomy 57 tHcy 57 cellular prion protein 57 relapsed SCLC 57 Fragile X gene 57 neurologic deficits 57 clinicopathological features